We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.
Filters applied:
Medicine & public health

Search Results

Showing 81-100 of 1,094 results

  2. Alopezie durch Anti-CGRP-Substanzen?

    Hans-Christoph Diener in MMW - Fortschritte der Medizin
    Article 15 September 2023

  4. Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy

    Background

    the interest of clinical reaseach in polymorphisms and epigenetics in migraine has been growing over the years. Due to the new era of...

    Damiana Scuteri, Maria Tiziana Corasaniti, ... Giacinto Bagetta in The Journal of Headache and Pain
    Article Open access 30 July 2021

  5. CGRP and PACAP-38 play an important role in diagnosing pediatric migraine

    Background

    An increasing number of studies have suggested that the important role of vasoactive peptides, such as pituitary adenylate...

    Junhui Liu, Guan Wang, ... **njie Liu in The Journal of Headache and Pain
    Article Open access 13 June 2022

  6. CGRP outflow into jugular blood and cerebrospinal fluid and permeance for CGRP of rat dura mater

    Background

    Calcitonin gene-related peptide (CGRP) is released from activated meningeal afferent fibres in the cranial dura mater, which likely...

    Miriam Risch, Birgit Vogler, ... Karl Messlinger in The Journal of Headache and Pain
    Article Open access 08 September 2021

  7. A Review of Calcitonin Gene-Related Peptide and Its Implications for Vestibular Disorders

    Purpose of review

    Calcitonin gene-related peptide (CGRP) is an inflammatory neuropeptide widely present throughout the body and involved in many...

    Richard Baron, Kristen K. Steenerson in Current Treatment Options in Neurology
    Article 23 May 2024

  8. CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience

    Background

    Calcitonin gene-related peptide (CGRP) (receptor) antibodies (erenumab, fremanezumab and galcanezumab) are increasingly used in...

    Armin Scheffler, Hannah Schenk, ... Dagny Holle in The Journal of Headache and Pain
    Article Open access 20 September 2021

  11. Hormonal influences in migraine — interactions of oestrogen, oxytocin and CGRP

    Migraine is ranked as the second highest cause of disability worldwide and the first among women aged 15–49 years. Overall, the incidence of migraine...

    Diana N. Krause, Karin Warfvinge, ... Lars Edvinsson in Nature Reviews Neurology
    Article 20 September 2021

  12. Initial experience with novel CGRP-receptor inhibitor therapy in Migraine in the United Arab Emirates: a retrospective observational study

    Background

    Erenumab is a calcitonin gene-related peptide (CGRP)-receptor antibody inhibiting CGRP function. CGRP is prominently involved in the...

    Bui Bao Khanh Dinh, Waseem Hamed Aziz, ... Derk Wolfgang Krieger in BMC Neurology
    Article Open access 14 December 2021

  13. Unmet Needs in the Acute Treatment of Migraine

    Migraine represents the most common neurologic disorder, ranking second among the world’s causes of disability [expressed as years lived with...

    Enrico Bentivegna, Silvia Galastri, ... Paolo Martelletti in Advances in Therapy
    Article Open access 09 November 2023

  14. Effectiveness of Anti-Calcitonin Gene-Related Peptide Medication in Vestibular Migraine: A Retrospective Cohort Study in an Asian Population

    Background

    Migraine and dizziness often coexist, with vestibular migraine (VM) presenting with vestibular symptoms and headaches. Calcitonin...

    Teppei Kouga, Toru Miwa, ... Yoshiaki Itoh in CNS Drugs
    Article 29 May 2024

  15. Effectiveness of dual migraine therapy with CGRP inhibitors and onabotulinumtoxinA injections: case series

    Aims

    Clinical trials for calcitonin gene-related peptide (CGRP) inhibitors excluded the concomitant use of onabotulinumtoxinA; thus, there is a lack...

    Tahlia Toni, Rayce Tamanaha, ... Kore Kai Liow in Neurological Sciences
    Article 18 August 2021

  16. A Brief Review of Gepants

    Purpose of Review

    Gepants are small molecules that antagonize calcitonin gene-related peptide (CGRP) receptors. Due to their favorable side effect...

    Diana Li, Jessica Abreu, Stewart J. Tepper in Current Pain and Headache Reports
    Article 02 August 2023

  18. New Migraine Drugs for Older Adults

    Migraine is one of the most widespread and burdensome diseases, affecting one in every seven individuals in the world, for an estimated global...

    Dilara Onan, William David Wells-Gatnik, ... Paolo Martelletti in Drugs & Aging
    Article 24 February 2023

  19. Characterization of erenumab and rimegepant on calcitonin gene-related peptide induced responses in Xenopus Laevis oocytes expressing the calcitonin gene-related peptide receptor and the amylin-1 receptor

    Background

    The clinical use of calcitonin gene-related peptide receptor (CGRP-R) antagonists and monoclonal antibodies against CGRP and CGRP-R has...

    Sanne Hage La Cour, Kiki Juhler, ... Inger Jansen-Olesen in The Journal of Headache and Pain
    Article Open access 26 May 2022

  20. Gepants — a long way to cure: a narrative review

    Calcitonin gene-related peptide (CGRP) is probably the most potent vasodilator in cerebral circulation. Forty years after its discovery, the new...

    Claudia Altamura, Nicoletta Brunelli, ... Fabrizio Vernieri in Neurological Sciences
    Article 02 June 2022
Did you find what you were looking for? Share feedback.